Piramal Pharma Limited (PPLPHARMA) Operating Income 2022–2026

Name: Piramal Pharma Limited (PPLPHARMA) operating income history 2022-2026
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-20

Piramal Pharma Limited annual operating income for fiscal 2026 was ₹1.5 billion, a decrease of 77.2% from ₹6.8 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

PPLPHARMA Annual Operating Income

Operating Income (annual)	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Operating Income (EBIT)	₹1.5B	₹6.8B	₹4.6B	(₹480M)	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PPLPHARMA Quarterly Operating Income

Operating Income (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-06-30	2025-03-31
Operating Income (EBIT)	(₹284M)	₹2.4B	(₹170M)	(₹906M)	₹3.2B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Operating Income at Comparable Companies

WOCKPHARMA Operating Income — Wockhardt Limited
1276 Operating Income — Jiangsu Hengrui Pharmaceuticals Co.,Ltd
NEULANDLAB Operating Income — Neuland Laboratories Limited
4540 Operating Income — Tsumura & Co.
4516 Operating Income — Nippon Shinyaku Co., Ltd.
3692 Operating Income — Hansoh Pharmaceutical Group Company Limited

More PPLPHARMA metrics: Revenue · Gross Profit · Net Income · EPS · Free Cash Flow

All PPLPHARMA financial statements → Interactive PPLPHARMA charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.